Bivalent Vaccine Effectiveness Among Adults Aged ≥65 Years During the BA.5-Predominant Period in Japan: The VENUS Study

BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron BA.5 became prevalent in July 2022 in Japan. Bivalent messenger RNA (mRNA) vaccines were approved as booster doses for individuals who received the primary series or booster dose by monovalent vaccines. We aimed to asse...

Descripción completa

Detalles Bibliográficos
Autores principales: Mimura, Wataru, Ishiguro, Chieko, Terada-Hirashima, Junko, Matsunaga, Nobuaki, Maeda, Megumi, Murata, Fumiko, Fukuda, Haruhisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10588616/
https://www.ncbi.nlm.nih.gov/pubmed/37869405
http://dx.doi.org/10.1093/ofid/ofad475

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10588616/
https://www.ncbi.nlm.nih.gov/pubmed/37869405
http://dx.doi.org/10.1093/ofid/ofad475

Ejemplares similares